BACKGROUND: Osteoprotegerin (OPG) is a secretory glycoprotein which belongs to the tumor necrosis factor receptor family. OPG immunoreactivity was demonstrated in normal blood vessels and in early atherosclerotic lesions. In a previous study, we showed that high serum OPG levels are associated with progression of coronary artery disease (CAD). OBJECTIVES: The present study was designed to assess the association between serum OPG level and long-term prognosis in patients with stable coronary artery disease. METHODS: We performed a prospective, observational cohort study in 225 subjects to examine whether serum OPG levels can predict cardiovascular mortality. The median OPG levels were 1.02 ng mL(-1) at baseline. RESULTS: During the follow-up (61 + or - 25 months), 27 deaths occurred including 13 cardiovascular deaths. When the subjects were divided into three groups according to serum OPG level, the group with high serum OPG showed a higher risk for cardiovascular mortality. A Multivariate Cox proportional hazards model indicated that the higher risk of cardiovascular death in the high OPG level group remained significant (hazards ratio of 7.44, 95%CI 0.92-60.30, highest vs. lowest OPG tertile). In contrast, serum OPG levels were not associated with non-cardiovascular mortality. CONCLUSIONS: Our data show that serum OPG levels are an independent predictor of cardiovascular mortality in patients with stable coronary artery disease.
BACKGROUND:Osteoprotegerin (OPG) is a secretory glycoprotein which belongs to the tumor necrosis factor receptor family. OPG immunoreactivity was demonstrated in normal blood vessels and in early atherosclerotic lesions. In a previous study, we showed that high serum OPG levels are associated with progression of coronary artery disease (CAD). OBJECTIVES: The present study was designed to assess the association between serum OPG level and long-term prognosis in patients with stable coronary artery disease. METHODS: We performed a prospective, observational cohort study in 225 subjects to examine whether serum OPG levels can predict cardiovascular mortality. The median OPG levels were 1.02 ng mL(-1) at baseline. RESULTS: During the follow-up (61 + or - 25 months), 27 deaths occurred including 13 cardiovascular deaths. When the subjects were divided into three groups according to serum OPG level, the group with high serum OPG showed a higher risk for cardiovascular mortality. A Multivariate Cox proportional hazards model indicated that the higher risk of cardiovascular death in the high OPG level group remained significant (hazards ratio of 7.44, 95%CI 0.92-60.30, highest vs. lowest OPG tertile). In contrast, serum OPG levels were not associated with non-cardiovascular mortality. CONCLUSIONS: Our data show that serum OPG levels are an independent predictor of cardiovascular mortality in patients with stable coronary artery disease.
Authors: Julia J Scialla; Mary B Leonard; Raymond R Townsend; Lawrence Appel; Myles Wolf; Matt J Budoff; Jing Chen; Eva Lustigova; Crystal A Gadegbeku; Melanie Glenn; Asaf Hanish; Dominic Raj; Sylvia E Rosas; Stephen L Seliger; Matthew R Weir; Rulan S Parekh Journal: Clin J Am Soc Nephrol Date: 2011-09-22 Impact factor: 8.237
Authors: Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer Journal: Heart Vessels Date: 2017-05-31 Impact factor: 2.037
Authors: Kate Ann Deuell; Andrea Callegari; Cecilia M Giachelli; Michael E Rosenfeld; Marta Scatena Journal: J Vasc Res Date: 2012-08-30 Impact factor: 1.934
Authors: Andrea Callegari; Matthew L Coons; Jerry L Ricks; Michael E Rosenfeld; Marta Scatena Journal: J Vasc Res Date: 2014-03-07 Impact factor: 1.934
Authors: Weena J Y Chen; Luuk J Rijzewijk; Rutger W van der Meer; Martijn W Heymans; Eelco van Duinkerken; Mark Lubberink; Adriaan A Lammertsma; Hildo J Lamb; Albert de Roos; Johannes A Romijn; Jan W A Smit; Jeroen J Bax; Mette Bjerre; Jan Frystyk; Allan Flyvbjerg; Michaela Diamant Journal: Cardiovasc Diabetol Date: 2011-07-19 Impact factor: 9.951